As suggested by a recent meta-analysis of 11 studies, the highest hazard ratio for survival is reached by CD163/CD68 TAM ratio, further confirming M2 TAM represent a robust outcome predictor for NHL patients, including DLBCL and FL [149]. Here, CD163 is linked to diffuse large B-cell lymphoma.